Citius Pharmaceuticals (CTXR) Competitors $1.55 +0.25 (+19.23%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.54 -0.01 (-0.65%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR vs. PDSB, KRON, VRPX, XFOR, CTOR, VNRX, AADI, HOWL, IMMX, and IPSCShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include PDS Biotechnology (PDSB), Kronos Bio (KRON), Virpax Pharmaceuticals (VRPX), X4 Pharmaceuticals (XFOR), Citius Oncology (CTOR), VolitionRx (VNRX), Aadi Bioscience (AADI), Werewolf Therapeutics (HOWL), Immix Biopharma (IMMX), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. PDS Biotechnology Kronos Bio Virpax Pharmaceuticals X4 Pharmaceuticals Citius Oncology VolitionRx Aadi Bioscience Werewolf Therapeutics Immix Biopharma Century Therapeutics Citius Pharmaceuticals (NASDAQ:CTXR) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking. Does the media prefer CTXR or PDSB? In the previous week, PDS Biotechnology had 15 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 16 mentions for PDS Biotechnology and 1 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 1.87 beat PDS Biotechnology's score of 0.28 indicating that Citius Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Citius Pharmaceuticals Very Positive PDS Biotechnology Neutral Is CTXR or PDSB more profitable? Citius Pharmaceuticals' return on equity of -51.69% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Citius PharmaceuticalsN/A -51.69% -37.60% PDS Biotechnology N/A -139.57%-67.22% Do analysts recommend CTXR or PDSB? Citius Pharmaceuticals presently has a consensus target price of $54.50, suggesting a potential upside of 3,416.13%. PDS Biotechnology has a consensus target price of $9.00, suggesting a potential upside of 614.29%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Citius Pharmaceuticals is more favorable than PDS Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do institutionals & insiders have more ownership in CTXR or PDSB? 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 12.1% of Citius Pharmaceuticals shares are owned by company insiders. Comparatively, 9.5% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has better earnings and valuation, CTXR or PDSB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius PharmaceuticalsN/AN/A-$39.14MN/AN/APDS BiotechnologyN/AN/A-$42.94M-$1.03-1.22 Which has more risk and volatility, CTXR or PDSB? Citius Pharmaceuticals has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Does the MarketBeat Community believe in CTXR or PDSB? Citius Pharmaceuticals received 137 more outperform votes than PDS Biotechnology when rated by MarketBeat users. However, 70.75% of users gave PDS Biotechnology an outperform vote while only 62.54% of users gave Citius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCitius PharmaceuticalsOutperform Votes21262.54% Underperform Votes12737.46% PDS BiotechnologyOutperform Votes7570.75% Underperform Votes3129.25% SummaryCitius Pharmaceuticals beats PDS Biotechnology on 8 of the 13 factors compared between the two stocks. Remove Ads Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.32M$6.90B$5.63B$7.84BDividend YieldN/A2.75%5.33%4.01%P/E RatioN/A7.2323.5118.72Price / SalesN/A218.61388.1990.75Price / CashN/A65.6738.1734.64Price / Book0.196.386.894.23Net Income-$39.14M$142.34M$3.20B$247.47M7 Day Performance1.97%-5.15%-3.06%-2.29%1 Month Performance-6.06%-7.55%1.51%-5.81%1 Year Performance-93.09%-11.06%9.35%-0.94% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals3.2961 of 5 stars$1.55+19.2%$54.50+3,416.1%-93.1%$13.32MN/A0.0020Positive NewsHigh Trading VolumePDSBPDS Biotechnology1.8447 of 5 stars$1.37flat$11.67+751.6%-68.2%$52.32MN/A-1.1820Earnings ReportAnalyst ForecastShort Interest ↓News CoverageGap DownKRONKronos Bio3.7848 of 5 stars$0.87-0.4%$1.63+87.5%-36.9%$52.30M$9.85M-0.61100Short Interest ↓VRPXVirpax Pharmaceuticals2.4639 of 5 stars$1.94-6.3%$3.00+54.6%-98.7%$51.53MN/A0.007Positive NewsGap DownXFORX4 Pharmaceuticals4.3898 of 5 stars$0.30-4.0%$3.50+1,086.4%-82.0%$51.23M$1.12M-3.2880Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap DownCTORCitius OncologyN/A$0.71+14.5%$3.00+322.5%N/A$50.80MN/A0.00N/ANews CoverageGap UpVNRXVolitionRx1.829 of 5 stars$0.55-0.4%$3.75+584.3%-27.3%$50.78M$1.29M-1.5280Analyst ForecastNews CoverageAADIAadi Bioscience1.2737 of 5 stars$2.05+4.6%$1.67-18.7%-18.4%$50.63M$25.07M-0.9040Positive NewsHOWLWerewolf Therapeutics2.7056 of 5 stars$1.12-0.9%$9.00+703.6%-84.1%$50.21M$1.89M-0.7340IMMXImmix Biopharma2.7316 of 5 stars$1.82+1.1%$7.00+284.6%-44.6%$50.07MN/A-2.149Earnings ReportNews CoverageIPSCCentury Therapeutics2.3027 of 5 stars$0.58+5.2%$5.00+756.6%-87.7%$49.63M$6.59M-0.32170Analyst ForecastAnalyst Revision Remove Ads Related Companies and Tools Related Companies PDSB Competitors KRON Competitors VRPX Competitors XFOR Competitors CTOR Competitors VNRX Competitors AADI Competitors HOWL Competitors IMMX Competitors IPSC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTXR) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTXR Stock Free CTXR Stock Alerts